InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Friday. The brokerage issued a sell rating on the stock.

A number of other brokerages also recently issued reports on NSPR. Piper Sandler reissued an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th. Lake Street Capital began coverage on shares of InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price target on the stock.

InspireMD Stock Up 0.7 %

Shares of InspireMD stock opened at $3.00 on Friday. The company’s fifty day simple moving average is $2.69 and its two-hundred day simple moving average is $2.69. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.42. The firm has a market cap of $78.25 million, a PE ratio of -4.00 and a beta of 0.98.

InspireMD (NYSE:NSPR) last posted its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The company had revenue of $1.81 million for the quarter, compared to analysts’ expectations of $1.74 million. During the same period last year, the firm earned ($0.15) earnings per share. As a group, sell-side analysts expect that InspireMD will post -0.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in InspireMD stock. Parkman Healthcare Partners LLC purchased a new stake in shares of InspireMD, Inc. (NYSE:NSPR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 104,081 shares of the company’s stock, valued at approximately $279,000. Parkman Healthcare Partners LLC owned approximately 0.42% of InspireMD as of its most recent SEC filing. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.